Intravenous NAD+,
does it really help with Slower biological aging and longer healthspan in healthy adults?
research showsIntravenous NAD+ is rated unknown for slowing aging or extending healthspan in healthy adults. The identified human study was an 11-person pilot that infused 750 mg of NAD+ over six hours and measured plasma and urine metabolites and short-term laboratory values; it did not measure aging rate, function, disease incidence, healthspan, or lifespan. A 2026 systematic review also found zero eligible intravenous or intramuscular NAD+ studies with clinical anti-aging or wellness outcomes. This route is separate from prior verdicts on oral NMN 031, NR 314, liposomal NAD 422, and niacinamide 386.
ads claimMarketing translates an essential cellular coenzyme, blood-metabolite changes, and oral-precursor research directly into cellular renewal, age reversal, and longer healthspan. Intravenous NAD+ studies have not measured those clinical outcomes, so there is no evidence-based effect size for lifespan extension.
Useful facts when choosing a product
- Intravenous NAD+ differs in exposure, metabolism, and risk from oral NMN, NR, niacinamide, or liposomal NAD, so verdicts 031, 314, 386, and 422 cannot be transferred to this route.
- The published pilot infused 750 mg of NAD+ at about 2 mg/min over six hours and included only eight active recipients and three saline controls.
- Intravenous treatment adds procedure risks absent from oral products, including infection, phlebitis, infiltration, fluid or electrolyte problems, and allergic reactions.
- Self-pay wellness compounding and infusion require verification of purity, sterility, content, storage, and practitioner standards, and long-term safety data are absent.
Chamgap Semantic Classification Code
Candidate index · review held
M.nad-plus.intravenous.slower-biological-aging-and-longer-healthspan.reduce.UNKMedicinal interventions > NAD+ > Intravenous > Slower biological aging and longer healthspan > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Grant and colleagues in 2019 infused 750 mg of NAD+ over six hours in eight of 11 participants and gave saline to three, measuring plasma and urine metabolites over eight hours. Plasma NAD+ did not rise immediately during the early infusion, with later changes in NAD+, NAM, meNAM, and ADPR, but no aging outcome was measured. A 2026 PRISMA review covering anti-aging and wellness literature from 2010 through October 2025 explicitly found no eligible intravenous or intramuscular NAD+ clinical outcome trial. Both long-term efficacy and long-term safety remain unknown.
Why this is classified as ?
There are zero human anti-aging or healthspan outcome trials of intravenous NAD+ itself. The 11-person pilot measured metabolite disposition and short-term laboratory values only, and the 2026 systematic review confirmed the absence of eligible intravenous or intramuscular NAD+ efficacy outcomes. The grade is therefore unknown and the score is null. Procedure, infection, and quality risks remain separate safety concerns.
Counterpoint. Participation in research differs from purchasing a commercial wellness infusion. Outside a trial, the uncertain benefit, cost, sterile compounding, and emergency-response capacity should be examined first.
Rejudgment record. New verdict — Applied the no-human-efficacy-literature criterion because the 11-person infusion study assessed NAD metabolite disposition only and the 2026 PRISMA review found zero eligible intravenous or intramuscular NAD+ clinical outcome trials for anti-aging or wellness
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Slower biological aging in healthy adults | ? | No clinical efficacy study has assessed human biological aging rate with intravenous NAD+ itself. |
| Longer functional healthspan in healthy adults | ? | No study has longitudinally assessed physical or cognitive function or disease-free survival. |
| Longer lifespan in healthy adults | ? | No intravenous NAD+ study has assessed human lifespan or mortality. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Grant R et al. 2019 | Small controlled disposition pilot | 11 participants; eight received intravenous NAD+ and three received saline | Investigators affiliated with NAD+ Research Inc. and a wellness center offering NAD infusions participated | Plasma and urine NAD+ and related metabolites over eight hours plus short-term safety laboratory tests | The study described metabolite changes during infusion but measured no aging-rate, function, disease, or healthspan endpoint. | Disposition context only, not clinical efficacy |
| Gallagher C and Emmanuel OO. 2026 | PRISMA-guided systematic review of preclinical and clinical evidence | Literature from 2010 through October 2025; zero eligible intravenous or intramuscular NAD+ clinical outcome trials | An author affiliation included a commercial aesthetics and wellness management company | Clinical efficacy, safety, and biomarkers for anti-aging and wellness | No eligible clinical efficacy outcome existed for intravenous or intramuscular NAD+ itself, and the intravenous NAD+ pharmacokinetic pilot was contextual only. | Confirmation of the efficacy-evidence gap |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-20).
Final verification and publication gate: Codex · Evidence date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Intravenous NAD+ x slower aging and longer healthspan in healthy adults — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/intravenous-nad-healthy-aging-healthspan/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.